TIDMABC
RNS Number : 1251N
ABCAM PLC
28 January 2021
ABCAM PLC
Appointment of Non-Executive Directors
28 January 2021, Cambridge, UK - Abcam plc (AIM: ABC; Nasdaq:
ABCM) ("Abcam"), a global leader in the supply of life science
research tools, is delighted to announce the appointments of Bessie
Lee and Mark Capone as non-executive Directors with immediate
effect.
Both Bessie and Mark bring extensive and complementary executive
and non-executive experience to the Board of Abcam.
Based in China, Bessie Lee is the Chief Executive Officer of
Withinlink, a China-based venture capital firm and start-up
incubator focused on marketing technology, which she founded in
2015. Prior to founding Withinlink, Bessie spent almost three
decades at WPP plc, holding Chief Executive Officer roles in China
for Mindshare, GroupM and finally WPP. Bessie is currently a
non-executive Director of Electrocomponents plc, Homeplus Digital
Co Ltd and Shanghai Fuge Information Technology Co Ltd. She also
acts as an Advisor to Didi Chuxing and Greater Pacific Capital.
Based in the US, Mark Capone is an accomplished life sciences
executive with more than 35 years' experience. He spent over 17
years with Myriad Genetics, latterly as Chief Executive Officer and
President, over which time he grew the company into a leading
global precision medicine company. Prior to joining Myriad
Genetics, Mark spent 17 years with Eli Lilly and Company in
positions across the entire value chain. Mark is currently the
Chief Executive Officer of Precision Medicine Advisors, a
consultancy for molecular diagnostics, pharmaceuticals and
biotechnology organizations, which he founded in 2020.
Peter Allen, Chairman of Abcam said: "I am delighted to welcome
Bessie and Mark to the Board of Abcam. Bessie brings deep insight
into customer and digital marketing dynamics in China, one of our
key strategic markets, whilst Mark brings a wealth of experience
within the life science sector and a first-hand understanding of
our diagnostic and biopharma customers. Their expertise will be
invaluable as we continue to work towards our long-term growth
plans."
Mark Capone will join the Remuneration Committee.
The composition of each of the Board Committees is confirmed as
follows:
Board Committee Membership
Nomination Committee Peter Allen (Chairman)
Louise Patten
Mara Aspinall
Giles Kerr
=========================
Remuneration Committee Louise Patten (Chairman)
Peter Allen
Mara Aspinall
Giles Kerr
Mark Capone
=========================
Audit and Risk Committee Giles Kerr (Chairman)
Louise Patten
Mara Aspinall
=========================
AIM Rules disclosures
Bessie Chien Ling Lee (age 55) holds or has held directorships
in the five years preceding her appointment at Abcam as
follows:
Current Directorships Previous Directorships
Withinlink (Shanghai) Investment Beixi (Shanghai) Trading Co
Management Co Ltd Ltd
=================================
Electrocomponents plc Shanghai Kuvera Ecommerce Co
Ltd
=================================
Homeplus Digital Co Ltd (formerly Weitewei Internet Technology
China Networks Systems Co Ltd) (Shanghai) Co Ltd
=================================
Shanghai Fuge Information Technology Dabang (Shanghai) Management
Co Ltd Co Ltd
=================================
Kinetic Advertising (Shanghai)
Co Ltd
=================================
GROWWW Communications Group
(formerly United Communications
Group)
=================================
Ecovacs Robotics Co Ltd
=================================
GROWWW Media Co Ltd
=================================
Save as disclosed above there are no additional disclosures to
be made in accordance with Schedule Two paragraph (g) of the AIM
Rules.
Mark Christopher Capone (age 58 ) holds or has held
directorships in the five years preceding his appointment at Abcam
as follows:
Current Directorships Previous Directorships
Precision Medicine Advisors Myriad Genetics Inc
LLC
====================================
Myriad RMB
====================================
Myriad Genetics Laboratories
Inc
====================================
Crescendo Bioscience Inc
====================================
American Clinical Laboratory
Association
====================================
Coalition for 21st Century Medicine
====================================
Assurex Health, Inc
====================================
Save as disclosed above there are no additional disclosures to
be made in accordance with Schedule Two paragraph (g) of the AIM
Rules.
For further information, please contact:
Abcam
+ 44 (0) 1223 696 000
Marc Perkins, Company Secretary
James Staveley, VP, Investor Relations
Numis - Nominated Advisor & Joint Corporate Broker
+ 44 (0) 20 7260 1000
Garry Levin / Duncan Monteith / Huw Jeremy
J.P.Morgan Cazenove - Joint Corporate Broker
+44 (0) 20 7742 4000
James Mitford / Hemant Kapoor
Morgan Stanley - Joint Corporate Broker
+ 44 (0) 207 425 8000
Tom Perry / Luka Kezic
FTI Consulting
+ 44 (0) 20 3727 1000
Ben Atwell / Natalie Garland-Collins
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
antibodies, assays and other research tools to address important
targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health.
Abcam's worldwide customer base of approximately 750,000 life
science researchers uses Abcam's antibodies, reagents, biomarkers
and assays. By actively listening to and collaborating with these
researchers, the Company continuously advances its portfolio to
address their needs. A transparent programme of customer reviews
and datasheets, combined with an industry-leading validation
initiative, gives researchers increased confidence in their
results.
Founded in 1998 and headquartered in Cambridge, UK, the Company
has served customers in more than 130 countries. Abcam's ordinary
shares are listed on the London Stock Exchange (AIM: ABC) and its
American Depositary Shares (ADSs) trade on the Nasdaq Global Market
(Nasdaq: ABCM).
For more information, please visit www.abcam.com or www.abcamplc.com
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Any express or implied statements contained in this announcement
that are not statements of historical fact may be deemed to be
forward-looking statements, including, without limitation,
statements regarding Abcam's portfolio and ambitions, expected
performance for first half 2021, as well as statements that include
the words "expect," "intend," "plan," "believe," "project,"
"forecast," "estimate," "may," "should," "anticipate" and similar
statements of a future or forward-looking nature. Forward-looking
statements are neither promises nor guarantees, but involve known
and unknown risks and uncertainties that could cause actual results
to differ materially from those projected, including, without
limitation: a regional or global health pandemic, including the
novel coronavirus ("COVID-19"), which has adversely affected
elements of our business, could severely affect our business,
including due to impacts on our operations and supply chains;
challenges in implementing our strategies for revenue growth in
light of competitive challenges; developing new products and
enhancing existing products, adapting to significant technological
change and responding to the introduction of new products by
competitors to remain competitive; failing to successfully identify
or integrate acquired businesses or assets into our operations or
fully recognize the anticipated benefits of businesses or assets
that we acquire; if our customers discontinue or spend less on
research, development, production or other scientific endeavours;
failing to successfully use, access and maintain information
systems and implement new systems to handle our changing needs;
cyber security risks and any failure to maintain the
confidentiality, integrity and availability of our computer
hardware, software and
internet applications and related tools and functions; failing
to successfully manage our current and potential future growth; any
significant interruptions in our operations; if our products fail
to satisfy applicable quality criteria, specifications and
performance standards; failing to maintain our brand and
reputation; our dependence upon management and highly skilled
employees and our ability to attract and retain these highly
skilled employees; and the important factors discussed under the
caption "Risk Factors" in Abcam's prospectus pursuant to Rule
424(b) filed with the U.S. Securities and Exchange Commission
("SEC") on 22 October 2020, which is on file with the SEC and is
available on the SEC website at www.sec.gov, as such factors may be
updated from time to time in Abcam's other filings with the SEC.
Any forward-looking statements contained in this announcement speak
only as of the date hereof and accordingly undue reliance should
not be placed on such statements. Abcam disclaims any obligation or
undertaking to update or revise any forward-looking statements
contained in this announcement, whether as a result of new
information, future events or otherwise, other than to the extent
required by applicable law.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAZZGZMRNDGMZM
(END) Dow Jones Newswires
January 28, 2021 02:00 ET (07:00 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From May 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024